Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: Avoiding a serious adverse drug interaction

Brad Moriyama, Oluwaseun Falade-Nwulia, Janice Leung, Scott R. Penzak, Caroline Jjingo, Xuan Huang, Stacey A. Henning, Wyndham H. Wilson, Thomas J. Walsh

Research output: Contribution to journalLetter

13 Scopus citations
Original languageEnglish
Pages (from-to)e877-e879
JournalMycoses
Volume54
Issue number6
DOIs
StatePublished - Nov 2011

Cite this

Moriyama, B., Falade-Nwulia, O., Leung, J., Penzak, S. R., Jjingo, C., Huang, X., Henning, S. A., Wilson, W. H., & Walsh, T. J. (2011). Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: Avoiding a serious adverse drug interaction. Mycoses, 54(6), e877-e879. https://doi.org/10.1111/j.1439-0507.2011.02016.x